🇺🇸 FDA
Patent

US 8101567

Heteroaryl-containing tripeptide HCV serine protease inhibitors

granted A61KA61K31/4965A61K38/21

Quick answer

US patent 8101567 (Heteroaryl-containing tripeptide HCV serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/4965, A61K38/21, A61P, A61P1/16